{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-26-005695","form_type":"8-K","ticker":"ZEOX","cik":"0001557376","company_name":"Zeo ScientifiX, Inc.","filed_at":"2026-05-27T11:35:28+00:00","discovered_at":"2026-05-27T11:40:01.388202+00:00","generated_at":"2026-05-27T11:40:50.874200+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ZeoScientifiX launches Physician-Led Patient Masterclass; trained 600+ physicians in past year","bullets":["Program formalizes patient education model that emerged from a physician-hosted event in Vero Beach, Florida.","Over 600 physicians trained in regenerative therapies across the Southeast in the past year.","Targets pain management, wound care, and orthopedics as permitted under Florida law.","Director of Growth Strategy cites strong patient demand and need for physician-led education on product quality.","General Manager states program scales clinical excellence and practice growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-005695","json":"https://secwatch.observer/filing/0001829126-26-005695.json","markdown":"https://secwatch.observer/filing/0001829126-26-005695.md","text":"https://secwatch.observer/filing/0001829126-26-005695.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557376/000182912626005695/0001829126-26-005695-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557376/000182912626005695/zeoscientifix_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T11:40:50.874200+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001449794-26-000012","ticker":"EMYB","company_name":"Embassy Bancorp, Inc.","filed_at":"2026-06-01T20:37:17+00:00","headline":"Embassy Bancorp expands stock repurchase program by additional $5M","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001449794-26-000012","json":"https://secwatch.observer/filing/0001449794-26-000012.json","markdown":"https://secwatch.observer/filing/0001449794-26-000012.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1449794/000144979426000012/0001449794-26-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1449794/000144979426000012/emyb-20260601x8k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063531","ticker":"CTXR","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2026-06-01T20:30:19+00:00","headline":"Citius Oncology reports Phase 1 combo data: 24% ORR, 33% in endometrial cancer; Phase 2 planned","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063531","json":"https://secwatch.observer/filing/0001213900-26-063531.json","markdown":"https://secwatch.observer/filing/0001213900-26-063531.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026063531/0001213900-26-063531-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026063531/ea0292904-8k_citius.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063530","ticker":"CTOR","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2026-06-01T20:30:18+00:00","headline":"Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063530","json":"https://secwatch.observer/filing/0001213900-26-063530.json","markdown":"https://secwatch.observer/filing/0001213900-26-063530.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026063530/0001213900-26-063530-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026063530/ea0292903-8k_citius.htm"},"side_by_side_evidence":null},{"accession":"0001636282-26-000075","ticker":"SYRE","company_name":"Spyre Therapeutics, Inc.","filed_at":"2026-06-01T20:01:39+00:00","headline":"Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001636282-26-000075","json":"https://secwatch.observer/filing/0001636282-26-000075.json","markdown":"https://secwatch.observer/filing/0001636282-26-000075.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000075/0001636282-26-000075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000075/syre-20260529.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063481","ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","filed_at":"2026-06-01T20:01:27+00:00","headline":"Oruka Therapeutics expands ORKA-001 license to include IBD; clinical dosing restrictions until 2028-2030","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063481","json":"https://secwatch.observer/filing/0001213900-26-063481.json","markdown":"https://secwatch.observer/filing/0001213900-26-063481.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000121390026063481/0001213900-26-063481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000121390026063481/ea0292876-8k_oruka.htm"},"side_by_side_evidence":null},{"accession":"0001606268-26-000032","ticker":"VIASP","company_name":"Via Renewables, Inc.","filed_at":"2026-06-01T19:06:57+00:00","headline":"Via Renewables to redeem all 1,884,935 shares of its 8.75% Series A Preferred at $25.00 per share plus dividends","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001606268-26-000032","json":"https://secwatch.observer/filing/0001606268-26-000032.json","markdown":"https://secwatch.observer/filing/0001606268-26-000032.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1606268/000160626826000032/0001606268-26-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1606268/000160626826000032/spke-20260601.htm"},"side_by_side_evidence":null},{"accession":"0000015847-26-000009","ticker":"BUKS","company_name":"BUTLER NATIONAL CORP","filed_at":"2026-06-01T16:41:32+00:00","headline":"CEO Christopher Reedy discloses ongoing cancer treatment; remains in role","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000015847-26-000009","json":"https://secwatch.observer/filing/0000015847-26-000009.json","markdown":"https://secwatch.observer/filing/0000015847-26-000009.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/15847/000001584726000009/0000015847-26-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/15847/000001584726000009/buks-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001437749-26-018930","ticker":"CPSH","company_name":"CPS TECHNOLOGIES CORP/DE/","filed_at":"2026-06-01T13:35:50+00:00","headline":"CPS Technologies closes $9.6M registered direct offering of 1.2M shares at $8.00/share","event_type":"other_material","sec_items":["1.01","5.03","8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-018930","json":"https://secwatch.observer/filing/0001437749-26-018930.json","markdown":"https://secwatch.observer/filing/0001437749-26-018930.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/814676/000143774926018930/0001437749-26-018930-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/814676/000143774926018930/cpsh20260528_8k.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}